SCHEDULE

We have scheduled our Programs dividing them into Day 1, Day 2, Day 3 in order to make it convenient for you to attend in absolute comfort.

25 Jan
Day 1

Keynote 1
No Image
Biography:

Giulio Tarro, graduated from Medicine School of Naples University. Research Associate at Division of Virology and Cancer Research, Children’s Hospital and Assistant Professor of Research Pediatrics, College of Medicine, Cincinnati, Ohio. He is a Professor of Oncological Virology at University of Naples. He worked for National Research Council, Rome, and for National Cancer Institute, Frederick Center, Maryland. He became Division Chief of Virology, and then Department Chief of Diagnostic Laboratories, D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006-. Since 2007 he is Chairman Committee on Biotechnologies and Virus Sphere World Academy Biomedical Technologies, UNESCO, and Adjunct Professor Department Biology Temple University College of Science and Techology, Philadelphia. Recipient of the Sbarro Health Research Organization lifetime achievement award (2010). His researches have been concerned with the characterization of specific virus-induced tumor antigens, which were the “finger-prints” left behind in human cancer. Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas. President Foundation de Beaumont Bonelli for Cancer Research.

Abstract:

Tumor liberated protein (TLP) has been previously described as a TAA (complex) present in the sera from lung cancer patients with early stage disease.

Since early detection improves overall survival in lung cancer, identification of screening biomarkers for patients at risk for the development of this disease represents an important target. Starting from the peptide epitope RTNKEASI previously isolated from TLP complexes, we generated a rabbit anti-RTNKEASI serum. This antiserum detected and immunoprecipitated a 55kDa protein band in the lysate of the lung cancer cell line A549. This protein band was identified as aldehyde dehydrogenase isoform 1A1 through mass spectrometry, revealing the molecular nature of at least one component of the previously described TLP complex. Next, we screened a cohort of 29 lung cancer patients (all histologies), 17 patients with non-neoplastic lung pathologies and 9 healthy donors for the presence of serum ALDH1A1 and global serum ALDH by enzyme-linked immunosorbent assay. This analysis indicated that the presence of ALDH was highly restricted to patients with lung cancer. Interestingly, the global ALDH test detected more lung cancer patients compared to the ALDH1A1-specific test, suggesting that other ALDH isoforms might add to the sensitivity of the assay. Our data suggest that ALDH levels may therefore be evaluated as part of a marker panel for lung cancer screening.

Finally, the ability of the immune system to recognize a TAA, enables the development of a vaccine approach for preventive and therapeutic application and represents a main target of this field of research.

Keynote 2

Pavlina Dolashka

Institute of Organic Chemistry with Centre of Phytochemistry ,Bulgaria

Title: Proteomic analyses of antitumore activity of Molluscs

No Image
Biography:

Prof. Dr. Dolashka’s group has wide experience in the isolation, purification, and characterization of biologically active compounds. She has more than 130 publications on these topics, 3 book chapters and 6 patents. Prof. Dolashka is Editor-in-board of 3 journals and representative IUPAC.She is coordinating several international research projects, sponsored by NATO (Brussels), the European Commission, Germany (DFG and BMBF), CNR (Italy), FWO (Belgium), China, and Ukraine. She also participates in National Research Program “BioActivMed” approved by DCM ? 658/14.09.2018 and BG05M2OP001-1.002-0019: "Clean Technologies for Sustainable Environment - Water, Waste, Energy for Circular Economy". Total value: 23 667 925.86 lv.

Abstract:

The hemolymph of mollusks is multi-component mixture from various biochemical and pharmacologically active substances with different masses and properties with potential application in medicine. The glycoprotein named hemocyanin (RvH) is major component of hemolymph isolated from marine snail Rapana venosa. RvH is oligomeric copper-containing respiratory glycoprotein with high molecular weight (about 8000 kDa) and complex quaternary structure, composed from two structural subunits RvH1 (420 kDa) and RvH2 (400 kDa). Each of them includes eight globular folded domains known as functional units with molecular masses of about 50 kDa. The antitumor activity of native RvH and its structural subunits were investigated in vitro on breast cancer cell lines: MCF-10? and MDA-MB-231 and HeLa a cell line derived from Human cervix epithelioid carcinoma. Our results demonstrated that the most effective inhibition of tumor cells MCF-10? and MDA-MB-231 was observed after treatment with RvH2.Moreover, the fraction from the hemolymph of marine snails of R. venosa, containing bioactive components with Mw between 50-100 kDa, exhibits the highest antitumor activity against two cancer cell lines – A375 skin cells isolated from malignant melanoma patient and HeLa. The mechanism of bioactive compounds was presented by proteomic analysis of untreated cells HeLa and after treatmed with the fraction. Proteins with altered expression were identification by MS and MS/MS analyses.

Keynote 3

Asli Giray

ALANYA ALAADDIN KEYKUBAT UNIVERSITY ,Turkey

Title: Targeting mitochondria in ovarian cancer and role of STARD4 gene

No Image
Biography:

She completed her PhD at the age of 34 years from Inonu University and postdoctoral studies from Sabanc? University from Turkey. She has worked Alanya Alaaddin Keykubat University, Faculty of Engineering Department of Genetic and Bioengineering in Turkey since 2017 She worked as a researcher on several projects (14 projects). She has published more than 12 papers.

Abstract:

Cancer continues to be a leading cause of death along with cardiovascular diseases and it’s a major health problem creating enormous socioeconomic burden on societies. In spite of the increase in patient survival rates promoted by increased screening and prevention efforts, much faster tumor genome sequencing and developed smart targeted-therapies, de novo or acquired chemoresistance still remains to be a significant factor for treatment failure in cancer therapeutics. BCL-2 protein family members regulate mitochondrial cell death pathway and the release of cytochrome c into the cytosol, which is the point of no return for cell death. Of note, we can predict how close is a cell to death by using a peptide-based mitochondrial analysis method, which is based on different binding affinities of proapoptotic BH3-only BCL-2 proteins to antiapoptotic BCL-2 proteins. STARD4 is a cytosolic protein that is involved in the transport of cholesterol to the mitochondrial outer membrane. The accumulation of mitochondrial cholesterol in cancer cells suppresses the release of cytochrome c. The cholesterol inhibits BAX activation by reducing the capacity of BAX to penetrate the membrane, thereby suppressing the tendency of cell death by inhibiting the formation of lipidic pores in the mitochondrial membrane. We worked ovarian cancer cell lines. Our works highlight the promising potential of using BH3 profiling assay.

Speaker 1
No Image
Biography:

Dr.?N. Furuichi?is?concerned?with?elucidating?hypersensitive?cell?death (HR)?of?host?plants with the recognition of the elicitor and Sup of the HR in plant cells. Current studies are examining to analyze the interaction of CDPK, NADPH oxidases ?AOS generating E) and sup of P. infestans in a single molecule analysis in the infected host cells by using the FCS-LSM.?He received his Ph.D. degree in Molecular Plant Pathology with Profs. K. Tomiyama (1981, Nagoya U.) and had postdoctoral of S. Nishimura (1982, Nagoya U.) and of A. J. Anderson (1988, Utah State U.:USU).  He was a Project PI of Plant Defense Center, Niigata U., (2003). Had the Visiting lab, Protein Institute, Osaka University (2005-2007). He had been a Fulbright Senior Scientist, USU.(1993-94) and as a Visiting Prof., USU (1993).

Abstract:

We have focused on the hypersensitive reaction (HR) and cell death in the plant defense between Phytophthora infestans, potato late blight pathogen, and host cultivars. We studied the Host-Selective-Toxin (HST), alternric acid and Non-host-selective-toxin, Solanapyron A, as a suppressor of Alternaria solani with the receptor candidate, Ca2+-dependent protein kinase (CDPK) by using binding assay and autophosphorylation assay. For the inhibition of HR in host cells, alternaric acid bind to the host membrane CDPK receptor, resulting in the inhibition of HR and cell death of host cells.  By using the FCC (Fluorescent Cross Correlation) LSM system, we have investigated the pathogen PAMPS elicitor and suppressor, and the HST from Alternaria solani, tomato early blight pathogen, and host membrane receptor signaling during State I-Sate II?Non-Active to Active transition states.  Of HR in potato and host cells. In conclusion, the CDPK-1 and CDPK-2 kinase of potato and tomato recognized the suppressor and HST of pathogens, resulting in the inhibition of NADPH oxidase and in the inhibition of occurrence of HR cell death.  

Speaker 2

Erika Seman?íková

2nd Department of Psychiatry, L. Pasteur University Hospital, ,Slovakia

Title: Proteomic Analysis of Cerebrospinal Fluid in Suicidal Patients - A Pilot Study

No Image
Biography:

Mrs. Erika Seman?íková, MD, PhD, is a psychiatrist in training working at theUniversity Hospital of L. Pasteur in Košice, Slovakia. She received a PhDdegree in Biochemistry while working at the Institute of Medical and ClinicalBiophysics, Faculty of Medicine at the P. J. Šafárik University in Košice,Slovakia. Her research interests include proteomics, suicide and molecularpsychiatry.

Abstract:

Despite the fact that proteomic analysis is becoming widely used in variousmedical fields its use in psychiatry is still very limited. We decided to study suicidal behaviourwith the use of proteomics to investigate proteins present in cerebrospinal fluid and platelets.We hypothetised that the same protein group could perhaps be detected in the plateletproteome and cerebrospinal fluid proteome in suicidal patients. Group of proteins identifiedin our sample by the STRING Database (mainly the complement and coagulation cascade andglycolysis/gluconeogenesis pathway) supports the idea of link between central nervoussystem and platelets („the periphery“). We also detected significantly higher levels of proteinsof 14-3-3 mediated signaling pathway in the cerebrospinal fluid of suicide attempters. Basedon this findings we suppose that alterations of glucose metabolism (especially utilisation ofglucose and altered response to oxidative stress) together with alterations in complement andcoagulation cascade and 14-3-3 mediated signaling pathway may play a role in theneurobiology of suicide. However, further research is needed to clarify whether the identifiedgroup of proteins can be used as potential peripheral biomarker candidates for suicidalbehaviour.

Speaker 3
No Image
Biography:

Dr. Xu is a senior director of research in Complete Genomics, Inc/MGI tech. His research interests includes DNA nanoball (DNB) based massively parrarell DNA sequencing, WGS/WES, DNB based applications, protein engingerering, enzymology. He did postdoctoral training in University of Minnesota, University of Pittsburgh and University of Texas at Austin. He earned his Ph.D. in biochemistry in 1989 from Shanghai Institute of Biochemistry, Chinease Academy of Science. He received his B.S. in chemistry from Zhejiang University, China.

Abstract:

DNA-protein interactions play pivotal roles in many cellular activities, such as replication, development, and DNA repair. Here we report a DNB-based on-chip Motif Finding (DocMF) system that utilizes next-generation-sequencing chips to profile protein binding or cleaving activity toward several hundred millions or billions of DNA sequences. Using DocMF, we successfully identified a variety of endonuclease recognition sites and the protospacer-adjacent motif (PAM) sequences of different CRISPR effector proteins. Compared with the widely used PAM depletion assay, our DocMF platform can simultaneously screen both 5’ and 3’ sequences adjacent to the protospacer to identify PAMs with high coverage using the same DNB library pool. For the well-studied SpCas9, our DocMF platform not only identified its common PAMs, 5’-NGG-3’, but also revealed a small proportion (~5%) of noncanonical 5’-NAG-3’ PAMs. We also used the DocMF to assay two uncharacterized Cas endonucleases, VeCas9 and BvCpf1. VeCas9 PAMs were not detected by the conventional PAM depletion method. However, DocMF revealed that VeCas9 requires the PAM sequences 5’-NNNRR-3’, whereas BvCpf1 uses the T-rich PAMs 5’-YYN-3’ for target DNA recognition. Moreover, after slightly changing the experimental protocol and analysis threshold, we observed that dCas9, a DNA binding protein lacking endonuclease activity, preferably binds to the previously reported PAMs 5’-NGG-3’. In summary, our studies demonstrate that DocMF is the first tool with the capacity to exhaustively assay both the binding and the cutting site preferences of different DNA-binding proteins.

Speaker 6

Adriana De Siervi

Argentina ,Instituto de Biologia y Medicina Experimental (IBYME-CONICET) Buenos Aires

Title: Liquid biopsies: a new emerging strategy for the early detection of breast cancer

No Image
Biography:

She obtained her Ph.D. in Molecular Biology at the Universisty of Buenos Aires, Argentina. She obtained a 5-years postdoctoral position at the NIH (USA). She obtained several awards from NIH, AACR and SAIC. Currently, she is the director of the Laboratory of Molecular Oncology and New Therapeuthic Targets (IBYME), Principal Investigator (CONICET) and member of Medical Comitee for Argentinean grants (ANPCYT). She obtained several grants.  Her lab investigates the molecular and cellular mechanisms for breast and prostate cancer progression, to identify novel biomarkers. She was convoqued as reviewer in several comitees (Ph.D, grants, fellows) and from high impact international journals.

Abstract:

Breast cancer (BCa) is the leading cause of death by cancer in women worldwide. Even though early diagnosis is improving the survival of BCa patients, more sensitive and specific tools are still necessary. Here, we propose the use of miRNAs as a biomarker alternative in BCa diagnosis. miRNAs are small non-coding RNA molecules that can be found in body fluids, such as urine or blood. Additionally, miRNAs can be release by tumors in early stages of BCa, even when they are undetectable by other diagnostic methods, which makes these molecules useful tools for early BCa detection.

Our aim was to identify circulating miRNAs (liquid biopsies) in plasma from patients with BCa using microarrays and mice model validation. Plasma from 30 patients was distributed into 5 clusters, according with their BCa stage: i) stages 0 and IA, ii) stage IIA, iii) stage IIB, iv) stage IIIA, and v) stages IIIB, IIIC and IV. As control, plasma from 32 healthy donors was distributed into 4 clusters. We hybridized miRNAs of each group using GeneChip® miRNA 4.0 Array (Affymetrix). Data analysis showed differentially circulating miRNAs in the plasma from BCa patients compared to healthy donors.

Analytical validation of the results was performed in NOD scid gamma (NSG) mice. We inoculated female mice with BCa cell line MDA-MB-231. After tumor growth, we sacrificed the mice to collect blood and tumor samples. Plasma from healthy animals was also obtained as control. We validated all miRNAs obtained from patients in the plasma mice.

Speaker 6
No Image
Biography:

Samy A. Abdel azim is Professor of molecular biology and Biochemistry At University of Cairo in 2010, In 2008: National research center of Functional and Molecular Biology. Completed his Bachelor degree in Biochemistry from University of Cairo 1982 and his Professional experience 2011. in 2009: Consultant for Clinical Analysis, 2006: Senior Specialist for Clinical Analysis, 1992: Resident in Clinical Analysis , Kasr eleini Pharmacy College Now, research focus on nanoparticles and cell biological and biochemical biomarkers utilized for early diagnosis of diseases by detection of serum microRNA

Abstract:

Nanotechnology is being actively developed for many applications in the medical field, including drug delivery, biosensors and medical imaging. These nanomaterials are being advanced as novel and more targeted treatments for difficult to manage diseases such as cancers. Additionally, the field of medical imaging can be improved with the ability for the specific targeting of diseased tissues at resolutions not capable with current technologies.

In contrast to the beneficial outcomes, using nanoparticles for drug delivery raises various safety concerns. The small size is beneficial, but it could have negative effects. This is a particularly important point as new and more durable materials are used in the production of these nanoparticles. Some nanoparticles can cause inflammation and fibrosis as a result of causing phagolysosomal membrane permeability, formation of reactive oxygen species and activation of the NLRP3 inflammasome . In our studies on TiO2 and CuO-NPS the studies exhibited that the most pronounced effect were displayed Oxidative stress, liver fibrosis, apoptosis and angiogenesis may be implicated in n-TiO2 or CuO-NPS-induced liver toxicity.

While, nanotechnology including the medical use of nanoparticles, hold great promise to improve the diagnosis and treatment of many diseases, we must not lose sight of the necessity to thoroughly test the nanomaterials so that they do not create unexpected adverse effects. Therefore, a situational approach should be used when assessing the benefits and drawbacks to using nanoparticles in medical diagnosis and treatment.

  • Europe : +44 2039665767
    Asia : +91 4048571057
    cellscience@magnuscorpus.com
  • Subscribe To Newsletter